STAT
NOVEMBER 18, 2024
The genetic sequence of the H5N1 bird flu virus that infected a teenager in British Columbia shows that the virus had undergone mutational changes that would make it easier for that version of H5N1 to infect people, scientists who have studied the data say. There’s currently no evidence the teenager, who remains in critical condition in hospital, infected anyone else.
Fierce Healthcare
NOVEMBER 18, 2024
Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. | Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 18, 2024
If he can make it past the Senate, Robert F. Kennedy Jr. will be the next secretary of Health and Human Services. Since the position was created, each secretary has had significant experience in public health, health care administration, or related government work. None has listed “spreading vaccine misinformation” as their primary health care experience.
Pharmacy Times
NOVEMBER 18, 2024
The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
NOVEMBER 18, 2024
Nothing brought Olivia more joy than when her daughter and grandchild visited her group home in Brooklyn in the early 2000s. Each hug and shared laugh lit up her face with pride like any mother’s, grounded in love, family, and connection. Olivia’s story should not be remarkable, but history almost denied her the chance to experience her family.
Pharmacy Times
NOVEMBER 18, 2024
Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 18, 2024
Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.
STAT
NOVEMBER 18, 2024
Cancer cases are on the rise among people under 50 — and researchers aren’t sure why. A recent study by the American Cancer Society found that 17 out of 34 cancer types were increasing among younger people. At the Milken Institute’s Future of Health Summit on Thursday, researchers and health care executives talked about efforts to detect cancers earlier, save lives, and get to the root of why cancers have begun to rise in this population.
Fierce Pharma
NOVEMBER 18, 2024
Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the boat as much as feared for the biopharma industry.
STAT
NOVEMBER 18, 2024
CHICAGO — Lipoprotein(a) is a risk factor for cardiovascular disease you may not hear about in your annual physical. Like LDL, or “bad” cholesterol, too much of the LDL-like particle can create plaque that clogs arteries, creating potential blockages that lead to heart attacks or strokes. It’s also implicated in aortic stenosis, when the aortic valve narrows, pinching blood supply to the rest of the body.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
NOVEMBER 18, 2024
Researchers analyzed the impact of the COVID-19 pandemic on outcomes for patients with pancreatic cancer living in England.
STAT
NOVEMBER 18, 2024
CHICAGO — In his presidential address to the American Heart Association on Sunday, Keith Churchwell, a clinical cardiologist and past hospital administrator, started right at the very beginning. Born in still-segregated Nashville, Tenn., he grew up in a household where academic achievement was expected, by his mother who earned advanced degrees while teaching in an elementary school and by his father whose work at a newspaper earned him the not always admiringly meant nickname
pharmaphorum
NOVEMBER 18, 2024
Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.A report in Spanish newspaper El Confidencial suggests that Brookfield is preparing to make a bid to take a 65% controlling stake in the drugmaker for €10.50 per share, worth around €7 billion ($7.4 billion).
STAT
NOVEMBER 18, 2024
CHICAGO — This year’s scientific sessions on the latest research in cardiovascular disease began not with the buzzy new obesity drugs but with a sobering look at progress stalling or even reversing in common chronic illnesses. The overture to the American Heart Association’s conference, coming as the organization celebrates its 100th year, began with Valentin Fuster of Mount Sinai Hospital lamenting the predicted shift in overall cardiovascular disease burden, worsenin
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
NOVEMBER 18, 2024
Drug Topics sat down with Adam J. James, PharmD, to discuss his journey from chain pharmacist to innovation leader at Rite Aid.
STAT
NOVEMBER 18, 2024
Regenxbio reported Monday the first clinical evidence showing improved muscle function in boys with Duchenne muscular dystrophy following treatment with its experimental gene therapy. The positive results from muscle-performance tests come from a small number of patients, but after consulting with the Food and Drug Administration, Regenxbio has expanded its current clinical trial so that it can support the submission of an accelerated approval application in 2026.
Pharmacy Times
NOVEMBER 18, 2024
Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.
STAT
NOVEMBER 18, 2024
This is the online version of STAT’s email newsletter Health Care Inc, delivered to your inbox every Monday. Sign up here. Hello, and thanks for letting me crash in your inbox. I’m still posting on the site formerly known as Twitter, proof that old habits are hard to break. But it’s evident more people have added Bluesky to their social media diet.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
NOVEMBER 18, 2024
Shortly after a disappointing trial readout for Syndax's menin inhibitor Revuforj in one form of leukaemia, the company has claimed FDA approval in another
Fierce Pharma
NOVEMBER 18, 2024
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. | The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters.
STAT
NOVEMBER 18, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk radiopharmaceuticals, GLP-1s, psychedelics, cardiomyopathy and more. The need-to-know this morning Syndax Pharmaceuticals won FDA approval for Revuforj , a new treatment for a genetically defined type of advanced leukemia.
pharmaphorum
NOVEMBER 18, 2024
Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 receptor agonist class.The results from the SUMMIT trial of tirzepatide in obese patients with heart failure with preserved ejection fraction (HFpEF) showed that Lilly's drug cut the risk of cardiovascular mortality and worsening heart failure events by 38% over a median follow-up of roughly two years.
Drug Topics
NOVEMBER 18, 2024
Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.
Fierce Pharma
NOVEMBER 18, 2024
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin. | Eisai has terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy. The company is also shutting down an extended access program in which patients were able to access the medication off-label.
Drug Topics
NOVEMBER 18, 2024
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, also discusses ways community pharmacists can collaborate with other healthcare professionals to enhance diabetes management.
STAT
NOVEMBER 18, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s been a busy November here at STAT, and it ain’t slowing down. I’m writing this on Friday afternoon and everyone’s on Zoom, discussing new coverage ideas. I guess I’m a bit biased, but I think we’ve been doing incredible work covering the election and its consequences.
Drug Topics
NOVEMBER 18, 2024
Michael Ganio, PharmD, BCPS, FASHP, discusses how the industry can become more resilient.
Pharmacy Times
NOVEMBER 18, 2024
The encouraging results suggest this low-cost, scalable strategy should be considered for population-level outreach globally to improve flu vaccination rates.
Drug Topics
NOVEMBER 18, 2024
Researchers evaluated the efficacy of a self-managed intervention vs enhanced usual care.
Fierce Pharma
NOVEMBER 18, 2024
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab
Pharmaceutical Technology
NOVEMBER 18, 2024
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically diagnosed FCS,
pharmaphorum
NOVEMBER 18, 2024
Using AI-powered PanEcho software for screening ECGs could deliver results more quickly and allow treatment to be started earlier.
Pharmaceutical Technology
NOVEMBER 18, 2024
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Expert insights. Personalized for you.
145 
Let's personalize your content